United States Últimas notícias

Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor being developed for potential cancer treatments.

SCYNEXIS (NASDAQ:SCYX) secured a contract with the Biomedical Advanced Research and Development Authority to support development of SCY-247, with potential funding of up to approximately $214 million.

Valley National Bancorp (NASDAQ:VLY) agreed to acquire Bluevine for approximately $340 million in a cash-and-stock transaction expected to include about 75% cash and 25% Valley common stock.

Soluna Holdings (NASDAQ:SLNH) amended its agreement with Bitdeer Technologies Group (NASDAQ:BTDR) subsidiary Dory Creek to expand Bitcoin mining operations at Soluna’s Project Kati 1 in South Texas.

TOYO (NASDAQ:TOYO) signed binding U.S. solar module supply agreements worth approximately $240 million with multiple U.S. customers since mid-June 2026.

Arvinas (NASDAQ:ARVN) dosed the first participant in a Phase 1/2 trial of ARV-6723, an investigational oral immuno-oncology candidate designed to degrade HPK1 in adults with advanced solid tumors.

Cosmos Health (NASDAQ:COSM) reported more than $20 million in implied revenue from Cana Laboratories’ contract manufacturing pipeline, based on management estimates over the expected duration of agreements.

Foresight Autonomous Holdings (NASDAQ:FRSX) signed a non-binding term sheet to acquire a 50.01% stake in a company advancing two data center projects in Poland.

TOYO (NASDAQ:TOYO) said it expects positive EBITDA for the second half of 2026 while withholding specific financial guidance due to ongoing U.S. trade and regulatory uncertainty.

AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.

Maris-Tech (NASDAQ:MTEK) received a US$10 million order to develop and supply video systems for next-generation manned airborne platforms under a multi-year project with Magam Safety.

TransDigm Group (NYSE:TDG) completed its acquisition of Prince & Izant for approximately $1.066 billion in cash, including certain tax benefits.